Comparing Corcept Therapeutics (CORT) & Its Competitors

Corcept Therapeutics (NASDAQ:CORT) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Corcept Therapeutics to similar businesses based on the strength of its institutional ownership, risk, earnings, dividends, profitability, valuation and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	$99.65 million	59.14
Corcept Therapeutics Competitors	$5.43 billion	$3.22 billion	552.59

Corcept Therapeutics’ rivals have higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Corcept Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Corcept Therapeutics’ rivals have a beta of -3.79, indicating that their average stock price is 479% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Corcept Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	2	5	0	2.50
Corcept Therapeutics Competitors	7798	13891	25787	1038	2.41

Corcept Therapeutics currently has a consensus price target of $139.50, suggesting a potential upside of 85.73%. As a group, “Pharmaceuticals” companies have a potential upside of 24.46%. Given Corcept Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than its rivals.

Profitability

This table compares Corcept Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	16.53%	22.56%	17.83%
Corcept Therapeutics Competitors	-2,380.39%	-218.78%	-15.59%

Institutional & Insider Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Corcept Therapeutics beats its rivals on 9 of the 13 factors compared.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.